Pharmaceutical Research and Manufacturers of America & Donald Trump

Pharmaceutical Research and Manufacturers of America: Pharmaceutical Research and Manufacturers of America (PhRMA) believes the CMS programs would be illegal and is challenging them.

Donald Trump: Donald Trump initiated the United States — Medicaid pilot program and other initiatives aimed at reducing U.S. prescription drug prices.

Pharmaceutical Research and Manufacturers of America: Pharmaceutical lobby group that criticized the order, emphasizing that schedule changes should be evidence-based.

Donald Trump: Signed the executive order, driving the policy change. His actions face widespread criticism from medical and public health organizations, potentially affecting his political standing and public trust in health agencies.

Pharmaceutical Research and Manufacturers of America: A spokesperson for Pharmaceutical Research and Manufacturers of America>>> expressed concern that the ruling could jeopardize the 'careful balance' of the Hatch-Waxman Act, potentially undermining incentives for researching new uses for existing medicines.

Donald Trump: President Donald Trump>>>'s administration supported Hikma Pharmaceuticals>>>'s appeal to the United States — Supreme Court of the United States>>>, aligning with the goal of encouraging generic competition and potentially lowering drug prices.

Pharmaceutical Research and Manufacturers of America: Pharmaceutical Research and Manufacturers of America criticized the new pharmaceutical tariffs, warning they would increase healthcare costs and jeopardize U.S. investments.

Pharmaceutical Research and Manufacturers of America: Pharmaceutical Research and Manufacturers of America, a trade association for pharmaceutical companies, states that pharmacy benefit managers and insurers create access and affordability barriers for patients.

Pharmaceutical Research and Manufacturers of America: Pharmaceutical Research and Manufacturers of America, a pharmaceutical company trade group, warned that Donald Trump's proposed tariffs on cutting-edge medicines could increase costs and jeopardize billions in U.S. investments.